|Flow Cytometry (Flow)||5 µL (0.5 µg)/test|
|Functional Assay (FN)||See 2 publications below|
|Miscellaneous PubMed (MISC)||See 2 publications below|
|Immunohistochemistry (IHC)||See 1 publications below|
|Immunoprecipitation (IP)||See 1 publications below|
|Tested Species reactivity||Human|
|Published species reactivity||Not Applicable|
|Host / Isotype||Mouse / IgG1, kappa|
|Storage buffer||PBS, pH 7.2, with 0.1% gelatin, 0.2% BSA|
|Contains||0.09% sodium azide|
|Storage conditions||4° C, store in dark, DO NOT FREEZE!|
Description: The TS2/16 monoclonal antibody reacts with human CD29, also known as integrin beta 1, an approximately 130 kDa single-pass transmembrane glycoprotein. CD29 complexes with one of nine integrin alpha subunits to form the very late antigen (VLA) subfamily of adhesion molecules. Integrin heterodimers containing CD29 are involved in cell-cell and cell-matrix adhesion. CD29 is expressed broadly on lymphocytes and monocytes, with lower levels of expression on granulocytes. The TS2/16 antibody has been found to possess activating activity for beta 1 integrins.
Applications Reported: This TS2/16 antibody has been reported for use in flow cytometric analysis.
Applications Tested: This TS2/16 antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells. This can be used at 5 µL (0.5 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test.
Excitation: 633-647 nm; Emission: 660 nm; Laser: Red Laser.
Filtration: 0.2 µm post-manufacturing filtered.
CD29 (beta1 integrin subunit, GPIIa) forms non-covalently linked heterodimers with at least 6 different alpha chains (alpha1-alpha6, CD49a-f) determining the binding properties of beta1 (VLA) integrins. These integrins mediate cell adhesion to collagen, fibronectin, laminin and other extracellular matrix (ECM) components. This interaction hinders cell death, whereas disruption of anchorage to ECM leads to apoptosis. Decreased expression of most beta1 integrins correlates with acquiring multidrug resistance of tumour cells during selection in presence of antitumour drug. In platelets, translocation of intracellular pool of beta1 integrins to the plasma membrane following thrombin stimulation. These integrins are also up-regulated in leukocytes during emigration and extravascular migration and appear to be critically involved in regulating the immune cell trafficking from blood to tissue, as well as in regulating tissue damage and disease symptoms related to inflammatory bowel disease. Through a beta1 integrin-dependent mechanism, fibronectin and type I collagen enhance cytokine secretion of human airway smooth muscle in response to IL-1beta.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: CD29; Fibronectin receptor subunit beta; Glycoprotein IIa; GPIIA; integrin beta 1; Integrin beta-1; integrin VLA-4 beta subunit; integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12); very late activation protein, beta polypeptide; VLA-4 subunit beta
Gene Aliases: CD29; FNRB; GPIIA; ITGB1; MDF2; MSK12; VLA-BETA; VLAB
UniProt ID: (Human) P05556
Entrez Gene ID: (Human) 3688
If an Invitrogen™ antibody doesn’t perform as described on our website or datasheet, we’ll replace the product at no cost to you, or provide you with a credit for a future purchase.*
Get expert recommendations for common problems or connect directly with an on staff expert for technical assistance related to applications, equipment and general product use.